$2.14MM to Raise $12.3MM? Are You Kidding Me?

I just picked up an article about an in-vitro diagnostics company that recently listed on London's AIM Exchange. The company was reminiscent of some previous opportunities I've worked with in in-vitro diagnostics, particularly those involving smart magnetic nanoparticles for better & faster blood marker detection. It was my previous affinity and understanding of biotech deals that originally drew me to the article. Then I read this:

A cursory look at Premaitha's financials as of September 2014 shows $8.4 million in cash on hand. This was after the $2.14 million spent by Premaitha to list on AIM through a reverse merger, a hefty sum considering they only raised $12.3 million in the offering.

Mind. Blown. Simple math indicates they spent roughly 17.4% for the cost of raising the capital in their public offering. That doesn't include the typical time cost to be listed or perhaps the equity cost to the original shareholders in the reverse merger itself. I would actually be very curious to see a detailed breakdown of the fees associated with this listing.

Given the sometimes high prices for a clean, trading public shell, I would imagine a good chunk of the cost was in acquiring the shell to trade. The question that immediately comes to mind is “was it worth it?” At some point, doing a reverse merger — unless you're merging into an inexpensive SPAC created in-house — doing a traditional IPO or even a DPO makes more sense than purchasing an existing shell.

There are some reasons where doing what Premaitha did would make sense. Such a decision likely involved speed and immediate access to the capital required. As always, the faster you wish to go, the more it will cost. It's still unfortunate that a company might be desperate enough to pay an excessive amount to gain access to the capital needed. With all the quantitative easing that's gone on of late, the cost of capital has decreased precipitously in the last decade and particularly in the last five years.

It's unfortunate that someone would be required to pay such a lofty sum for access to the public markets. I guess the prestige is worth it for some.

Breaking Down the True Cost of Going Public

The Premaitha case illustrates a broader truth: the all-in cost of a public listing is almost always higher than founders anticipate. When evaluating any path to the public markets, it helps to separate costs into three distinct buckets:

• Direct transaction fees — underwriter discounts, legal counsel, accounting and audit fees, exchange listing fees, and transfer agent costs. In a traditional IPO, these alone can run 7–10% of gross proceeds; in a reverse merger the structure differs but the aggregate cost can be comparable or worse.
• Indirect opportunity costs — management time diverted from operations during a process that routinely spans six to eighteen months. Key executives who should be focused on customers and product are instead consumed by roadshows, SEC comment letters, and investor relations.
• Ongoing compliance burden — once public, a company must sustain annual and quarterly reporting, Sarbanes-Oxley controls (for larger registrants), and investor relations infrastructure. This recurring overhead, easily several hundred thousand dollars per year for a smaller public company, is a permanent tax on operations.

Understanding how much it costs to pursue a capital raise — whatever the route — is an essential first step in deciding whether going public is the right path at all. Our guide to how much it costs to raise capital walks through the full fee landscape across equity, debt, and hybrid structures.

Reverse Mergers vs. Traditional IPOs: A Framework for Comparison

The reverse merger has genuine advantages in certain situations: speed to market, avoidance of the full SEC registration comment cycle, and the ability to access a publicly traded currency without a full roadshow. But Premaitha's experience highlights a scenario where the benefits were outweighed by the costs.

A structured comparison is useful when advising early-stage companies on their capital markets options:

• Traditional S-1 IPO — longest process (12–18 months typically), highest disclosure burden, but potentially the most efficient route for companies raising large amounts where underwriter syndication adds real distribution value.
• Reg A+ (Mini-IPO) — a lighter-touch SEC registration allowing up to $75 million raised from the public. Lower legal costs and faster timeline, though investor base and liquidity tend to be shallower.
• Direct Public Offering (DPO) — company sells shares directly to the public without an underwriter, eliminating the underwriting discount but also removing the distribution network an underwriter provides.
• Reverse Merger into a Shell — fastest route to a trading ticker, but shell quality varies enormously. Clean SPACs formed in-house are a different proposition than purchasing an aged shell with legacy liabilities.

For a thorough comparison of these paths, our overview of Reg A+, S-1, and reverse merger options covers the regulatory and practical tradeoffs in detail.

When the Cost of Public Capital Makes Private Alternatives More Attractive

The 17.4% cost of capital in Premaitha's offering should prompt any founder to ask a pointed question: could the same capital have been raised privately at a lower all-in cost? In many cases for growth-stage companies, the answer is yes — at least in the short term.

Private alternatives worth evaluating include institutional venture or growth equity, revenue-based financing, or acquisition financing structures that use the target's own assets and cash flows to support leverage. Each involves its own cost — management fees, equity dilution, or interest — but the transaction costs are typically lower and the ongoing compliance burden is absent.

For companies specifically pursuing a capital raise, working through a structured preparation process before approaching any market — public or private — materially improves outcomes. Investors and underwriters price uncertainty into their terms; a company that arrives with audited financials, a clear use-of-proceeds narrative, and investor-ready materials negotiates from a stronger position.

Frequently Asked Questions

What is a typical underwriting discount for an IPO?

For U.S. IPOs, the underwriting discount (also called the gross spread) has historically clustered around 7% of gross proceeds for smaller offerings, though larger deals sometimes negotiate lower spreads. This fee is paid to the syndicate of underwriters and does not include legal, accounting, or exchange-related costs, which add several percentage points on top.

Why might a reverse merger cost more than a traditional IPO?

In a reverse merger, the acquiring company pays for the shell — which can be expensive if the shell has a clean trading history and no legacy liabilities — and still incurs legal and accounting fees to complete the transaction and bring SEC filings current. When aggregated, these costs can rival or exceed a Reg A+ offering, but without the distribution network that a traditional underwriter provides.

What ongoing costs should a small public company budget for?

Small reporting companies should generally budget for annual audit fees, SEC filing counsel, transfer agent fees, D&O insurance, and investor relations. For many micro-cap companies this totals several hundred thousand dollars annually — a meaningful overhead burden that erodes the value of the public listing if the company cannot access the market regularly to raise capital at favorable terms.

When does raising equity for an acquisition make more sense than going public?

If a company's primary objective is to fund a specific acquisition rather than to create a publicly traded currency, raising equity specifically for an acquisition through a private placement or sponsor-backed structure is often faster, cheaper, and less disruptive to management. The public markets make most sense when the company needs recurring access to large amounts of capital or wants to use stock as deal consideration at scale.